Matinas BioPharma gets NYSE American notice of noncompliance
On Aug. 31, 2026, Matinas BioPharma received a NYSE American notice of noncompliance with Section 1003(a)(i). The exchange cited stockholders’ equity of $1.8 million versus a $2.0 million minimum and losses in recent years.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.